Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (71-80 of 325) with videos related to

Pageof 33
Sort By:
Biochimica Et Biophysica Acta. Reviews on Cancer|October 25, 2017
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practiceDebora de Melo Gagliato, Javier Cortes, Giuseppe Curigliano, et al.
Trends in Cancer|March 23, 2024
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatmentsVictoria C Rayson, Michael A Harris, Peter Savas, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Beyond trastuzumab: new treatment options for HER2-positive breast cancerKamal S Saini, Hatem A Azim, Otto Metzger-Filho, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2013
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerSherene Loi, Sandra Pommey, Benjamin Haibe-Kains, et al.
Breast Cancer Research and Treatment|June 6, 2015
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancerDaniele Generali, Sergio Venturini, Carla Rognoni, et al.
Nature Cancer|February 5, 2022
Securing the future of the clinician-scientistKaren Noble, Joanna Owens, Fabrice André, et al.
BMC Medicine|August 25, 2015
Relevance of tumor-infiltrating lymphocytes in breast cancerSathana Dushyanthen, Paul A Beavis, Peter Savas, et al.
Cancer Research|January 9, 2016
Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T CellsDeepak Mittal, Franco Caramia, Stefan Michiels, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 19, 2007
Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experienceSabine Roithmaier, Andrew M Haydon, Sherene Loi, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyJohn Stagg, Sherene Loi, Upulie Divisekera, et al.
Pageof 33

Showing results (71-80 of 325) with videos related to

Sort By:
Pageof 33
Biochimica Et Biophysica Acta. Reviews on Cancer|October 25, 2017
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practiceDebora de Melo Gagliato, Javier Cortes, Giuseppe Curigliano, et al.
Trends in Cancer|March 23, 2024
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatmentsVictoria C Rayson, Michael A Harris, Peter Savas, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Beyond trastuzumab: new treatment options for HER2-positive breast cancerKamal S Saini, Hatem A Azim, Otto Metzger-Filho, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2013
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerSherene Loi, Sandra Pommey, Benjamin Haibe-Kains, et al.
Breast Cancer Research and Treatment|June 6, 2015
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancerDaniele Generali, Sergio Venturini, Carla Rognoni, et al.
Nature Cancer|February 5, 2022
Securing the future of the clinician-scientistKaren Noble, Joanna Owens, Fabrice André, et al.
BMC Medicine|August 25, 2015
Relevance of tumor-infiltrating lymphocytes in breast cancerSathana Dushyanthen, Paul A Beavis, Peter Savas, et al.
Cancer Research|January 9, 2016
Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T CellsDeepak Mittal, Franco Caramia, Stefan Michiels, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 19, 2007
Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experienceSabine Roithmaier, Andrew M Haydon, Sherene Loi, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyJohn Stagg, Sherene Loi, Upulie Divisekera, et al.
Pageof 33